Your browser doesn't support javascript.
loading
CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.
Alldred, Melissa J; Chao, Helen M; Lee, Sang Han; Beilin, Judah; Powers, Brian E; Petkova, Eva; Strupp, Barbara J; Ginsberg, Stephen D.
Afiliación
  • Alldred MJ; Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York.
  • Chao HM; Department of Psychiatry, New York University Langone Medical Center, New York, New York.
  • Lee SH; Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York.
  • Beilin J; Department of Psychiatry, New York University Langone Medical Center, New York, New York.
  • Powers BE; Center for Biomedical Imaging and Neuromodulation, Nathan Kline Institute, Orangeburg, New York.
  • Petkova E; Child and Adolescent Psychiatry, New York University Langone Medical Center, New York, New York.
  • Strupp BJ; Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York.
  • Ginsberg SD; Department of Psychology, Cornell University, Ithaca, New York.
Hippocampus ; 28(4): 251-268, 2018 04.
Article en En | MEDLINE | ID: mdl-29394516
Although there are changes in gene expression and alterations in neuronal density and afferent inputs in the forebrain of trisomic mouse models of Down syndrome (DS) and Alzheimer's disease (AD), there is a lack of systematic assessments of gene expression and encoded proteins within individual vulnerable cell populations, precluding translational investigations at the molecular and cellular level. Further, no effective treatment exists to combat intellectual disability and basal forebrain cholinergic neurodegeneration seen in DS. To further our understanding of gene expression changes before and following cholinergic degeneration in a well-established mouse model of DS/AD, the Ts65Dn mouse, we assessed RNA expression levels from CA1 pyramidal neurons at two adult ages (∼6 months of age and ∼11 months of age) in both Ts65Dn and their normal disomic (2N) littermates. We further examined a therapeutic intervention, maternal choline supplementation (MCS), which has been previously shown to lessen dysfunction in spatial cognition and attention, and have protective effects on the survival of basal forebrain cholinergic neurons in the Ts65Dn mouse model. Results indicate that MCS normalized expression of several genes in key gene ontology categories, including synaptic plasticity, calcium signaling, and AD-associated neurodegeneration related to amyloid-beta peptide (Aß) clearance. Specifically, normalized expression levels were found for endothelin converting enzyme-2 (Ece2), insulin degrading enzyme (Ide), Dyrk1a, and calcium/calmodulin-dependent protein kinase II (Camk2a), among other relevant genes. Single population expression profiling of vulnerable CA1 pyramidal neurons indicates that MCS is a viable therapeutic for long-term reprogramming of key transcripts involved in neuronal signaling that are dysregulated in the trisomic mouse brain which have translational potential for DS and AD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Colina / Síndrome de Down / Células Piramidales / Fármacos Neuroprotectores / Región CA1 Hipocampal / Enfermedad de Alzheimer Límite: Animals Idioma: En Revista: Hippocampus Asunto de la revista: CEREBRO Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Colina / Síndrome de Down / Células Piramidales / Fármacos Neuroprotectores / Región CA1 Hipocampal / Enfermedad de Alzheimer Límite: Animals Idioma: En Revista: Hippocampus Asunto de la revista: CEREBRO Año: 2018 Tipo del documento: Article